Risdiplam (Evrysdi®)
Risdiplam (Evrysdi®) was added to the High Tech Arrangement on 1st September 2023. A Managed Access Protocol (MAP) is in place for Risdiplam. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of Risdiplam under the High Tech Arrangement.
The prescribing of Risdiplam under the High Tech Arrangement is confined to consultant neurologists with experience in the diagnosis and management of spinal muscular atrophy (SMA) in specialist centre(s) in Ireland, who have agreed to the terms of the MAP and have been approved by the HSE.
The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
A copy of the HSE-Managed Access Protocol for Risdiplam and the application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie
Click here for a Data Snapshot on treatments for SMA.